Klinar CRO

Klinar CRO was established in January 2009 as an Optimum CRO enterprise for the international trials conducted in Turkey. Optimum CRO is one of the first CROs established in Turkey in 2000. In September 2018, we decided to merge our companies back together again in order to be stronger in our projects we are carrying out under the name of Klinar CRO.

Visit Website

Locations

  • Europe

Therapeutic Areas

  • Bone / Osteoporosis
  • Cardiovascular
  • CNS
  • Dental and Oral Health
  • Dermatology
  • Diabetes
  • Endocrine
  • Gastrointestinal / Hepatology
  • Genetic Diseases
  • Hematology
  • Hepatology
  • Immunology
  • Infectious Diseases
  • Inflammation
  • Internal Diseases
  • Metabolic Diseases
  • Musculoskeletal
  • Nephrology
  • Neurology
  • Nutrition and Health
  • Obstetrics / Gynecology
  • Oncology
  • Ophthalmology
  • Orthopedics
  • Otolaryngology/ENT (Ear/Nose/Throat)
  • Pediatrics / Neonatology
  • Pharmacology / Toxicology
  • Podiatry
  • Psychiatry
  • Pulmonary
  • Rare Disease
  • Respiratory
  • Rheumatology
  • Sleep
  • Surgery
  • Thrombosis
  • Urology
  • Vaccines

Klinar CRO has staff including CRAs, PMs, QC, SCs and data management units which are located in the main office based in Ankara, the capital city of Turkey. With its high development rate, Klinar CRO is one of the leading and experienced foundations for conduct, organization and improvement of clinical researches in Turkey. Currently, KlinAR CRO has become one of the first certified CRO to be approved by the Ministry of Health in Turkey, working in compliance with the principles of “Guideline For Good Clinical Practices”. KlinAR CRO also has additional quality certificate as ISO:27001 Data Safety and Integrity Certificate. In addition to the main office based in Ankara, depending on the project needs, KlinAR may provide home based personnel in several cities. With Optimum CRO’s leading experience KlinAR CRO and its team has a deep experience over the clinical trials of different phases and post marketing surveillance studies. We provide; Regulatory Services (EC and RA (Ministry of Health) Submissions